Journal of Clinical and Experimental Hematopathology
Online ISSN : 1880-9952
Print ISSN : 1346-4280
ISSN-L : 1346-4280
Original Article
Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines
Chaoya Ma, Hasita Horlad, Cheng Pan, Hiromu Yano, Koji Ohnishi, Yukio Fujiwara, Masao Matsuoka, Aeju Lee, Takuro Niidome, Ryuya Yamanaka, Motohiro Takeya, Yoshihiro Komohara
Author information
Keywords: PD-L1, PD-L2, Stat3, lymphoma
JOURNAL FREE ACCESS

2017 Volume 57 Issue 1 Pages 21-25

Details
Abstract

Recent studies have indicated the significance of immune checkpoint molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell immunoglobulin and mucin domain-containing molecule-3 for anti-tumor immune responses. We previously investigated PD-1 ligand 1/2 (PD-L1/2) expression in lymphoma cell lines, and found that PD-L1/2 is expressed on the adult T-cell leukemia/lymphoma (ATL-T) and B-cell lymphoma (SLVL) cell lines. In the present study, we investigated whether the Stat3 inhibitor WP1066 abrogated PD-L1/2 expression in lymphoma cell lines. Incubation with WP1066 inhibited lymphoma cell growth and induced cell apoptosis. PD-L1/2 expression in the ATL-T, SLVL, and human brain malignant lymphoma (HKBML) cell lines was significantly abrogated by WP1066 treatment. These data indicated that a Stat3 inhibitor abrogated PD-L1/2 expression in lymphoma cells. Such an inhibitor is therefore considered to be useful for additional immunotherapy in patients with advanced lymphoma.

Content from these authors
© 2017 by The Japanese Society for Lymphoreticular Tissue Research
Previous article Next article
feedback
Top